Carisma Therapeutics, Inc. (CARM) Stock Analysis

Carisma Therapeutics, Inc. (CARM) Healthcare & Pipeline Overview

Carisma Therapeutics, Inc. pioneers CAR-macrophage therapies targeting solid tumors, differentiating itself through macrophage-based immunotherapy. With a strategic collaboration with Moderna, the company leverages its expertise in macrophage biology and CAR engineering to address unmet needs in cancer treatment within the competitive biotechnology sector.

What Is the Investment Thesis for CARM?

Carisma Therapeutics, Inc. presents a unique investment opportunity within the biotechnology sector, driven by its innovative CAR-macrophage technology. The company's strategic collaboration with Moderna provides validation and resources for clinical development. Key value drivers include successful clinical trial outcomes, regulatory approvals, and expansion of the CAR-macrophage platform to additional solid tumor targets. The company's high gross margin of 98.1% indicates strong potential for profitability upon commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established cancer therapies. Investors should monitor clinical trial data, regulatory milestones, and competitive dynamics to assess the long-term potential of Carisma Therapeutics, Inc.

Based on FMP financials and quantitative analysis

CARM Key Highlights

Strategic collaboration with Moderna Inc. validates CAR-macrophage technology and provides resources for development.

• High gross margin of 98.1% suggests strong potential for profitability upon commercialization.
• Focus on CAR-macrophage therapies differentiates Carisma from competitors in the immunotherapy space.
• Based in Philadelphia, a hub for biotechnology innovation and research.
• Beta of 1.31 indicates higher volatility compared to the overall market.

Who Are CARM's Competitors?

CARM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CARM's Key Strengths?

Innovative CAR-macrophage technology.

• Strategic collaboration with Moderna Inc.
• High gross margin potential.
• Experienced leadership team.

What Are CARM's Weaknesses?

Early-stage clinical development.

• Dependence on clinical trial outcomes.
• Limited commercialization experience.
• Small company size.

What Could Drive CARM Stock Higher?

Clinical trial data releases for CAR-macrophage therapies.

• Potential regulatory approvals from the FDA.
• Expansion of the CAR-macrophage platform to new tumor types.
• Strategic partnerships and collaborations with research institutions.
• Advancements in macrophage biology and CAR engineering.

What Are the Key Risks for CARM?

Financial-distress signal — its Altman Z-Score of -45.90 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-28.9%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
• Clinical trial failures and setbacks.
• Regulatory hurdles and delays.
• Competition from established cancer therapies.
• Dependence on clinical trial outcomes.
• Limited commercialization experience.

What Are the Growth Opportunities for CARM?

• Expansion of CAR-Macrophage Platform: Carisma has the opportunity to expand its CAR-macrophage platform to target additional solid tumor types. This includes exploring new CAR designs and target antigens to address a broader range of cancers. The market for targeted cancer therapies is expected to grow significantly, offering substantial revenue potential for Carisma as it broadens its pipeline. Timeline: Ongoing, with continuous research and development efforts.
• Advancement of Clinical Trials: Carisma's growth is heavily dependent on the successful advancement of its clinical trials. Positive data from Phase 1 and Phase 2 trials could lead to accelerated regulatory approval and commercialization. The market for successful cancer therapies is substantial, with potential blockbuster drugs generating billions in annual revenue. Timeline: Anticipated within the next 2-3 years.
• Strategic Partnerships and Collaborations: Carisma can leverage strategic partnerships and collaborations to accelerate its research and development efforts. Collaborating with leading research institutions and pharmaceutical companies can provide access to new technologies, funding, and expertise. The value of such partnerships can range from millions to billions of dollars, depending on the scope and potential of the collaboration. Timeline: Ongoing.
• Regulatory Approvals and Commercialization: Obtaining regulatory approvals from the FDA and other regulatory agencies is crucial for Carisma's growth. Successful commercialization of its CAR-macrophage therapies would generate significant revenue and establish Carisma as a leader in the immunotherapy space. The market for approved cancer therapies is highly lucrative, with potential for rapid market penetration. Timeline: Anticipated within the next 3-5 years.
• Intellectual Property Protection: Strengthening its intellectual property portfolio is essential for Carisma to maintain a competitive advantage. Securing patents for its CAR-macrophage technology and related innovations will protect its market position and attract potential investors. The value of a strong IP portfolio can significantly enhance the company's valuation and long-term growth prospects. Timeline: Ongoing.

What Are CARM's Competitive Advantages?

• Proprietary CAR-macrophage technology platform.
• Strategic collaboration with Moderna Inc.
• Expertise in macrophage biology and CAR engineering.
• Strong intellectual property portfolio.

What Does CARM Do?

Carisma Therapeutics, Inc., founded in 2016 and based in Philadelphia, is a biopharmaceutical company dedicated to developing innovative cancer therapies. The company specializes in chimeric antigen receptor (CAR) macrophages, a novel approach to treating solid tumors. Carisma's technology harnesses the innate and adaptive immune response by leveraging advances in macrophage biology, CAR engineering, and adoptive cellular therapy. Macrophages, crucial components of the immune system, are engineered to express CARs, enabling them to specifically target and destroy cancer cells. This approach aims to overcome the limitations of traditional cancer treatments by enhancing the body's natural ability to fight tumors. Carisma's lead product candidates are designed to address a range of solid tumors, offering potential solutions for patients with limited treatment options. The company has a strategic collaboration agreement with Moderna Inc., further validating its technology and providing resources for development and clinical trials. Carisma Therapeutics, Inc. operates primarily in the United States, focusing on research, development, and clinical advancement of its CAR-macrophage platform.

What Products and Services Does CARM Offer?

• Develops chimeric antigen receptor (CAR) macrophages for solid tumor treatment.
• Engineers macrophages to target and destroy cancer cells.
• Leverages macrophage biology and CAR engineering for immunotherapy.
• Conducts research and development to advance its CAR-macrophage platform.
• Collaborates with Moderna Inc. on therapeutic development.
• Focuses on addressing unmet needs in cancer treatment.

How Does CARM Make Money?

• Develops and patents CAR-macrophage technology.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapies.
• Seeks regulatory approvals from agencies like the FDA.
• Commercializes approved therapies through direct sales or partnerships.

What Industry Does CARM Operate In?

Carisma Therapeutics, Inc. operates within the rapidly evolving biotechnology industry, specifically in the field of immunotherapy. The market for cancer therapies is substantial and growing, driven by increasing cancer incidence and advancements in treatment options. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing various immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors. Carisma's CAR-macrophage approach offers a differentiated strategy by leveraging the unique properties of macrophages to target solid tumors.

Who Are CARM's Key Customers?

• Patients with solid tumors who have limited treatment options.
• Hospitals and cancer centers that administer CAR-macrophage therapies.
• Pharmaceutical companies seeking to collaborate on cancer treatment development.

Carisma Therapeutics, Inc. Financial Trajectory

Carisma Therapeutics, Inc. (CARM) reported $45.3M in revenue for Q3 FY2025, based on the latest filing compared to the prior quarter. The company recorded net income of $44.7M, with diluted EPS of $1.07. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, CARM averaged $0.05 in diluted EPS.

Company Profile

Carisma Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO Craig R. Jalbert. CARM has traded publicly since 2014.

Return on equity for Carisma Therapeutics, Inc. stands at -28.9%, a gauge of how efficiently it converts shareholder capital into profit. CARM trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.50x. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching.

Carisma Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -45.90 places it in the distress zone, a signal of elevated financial risk.

Carisma Therapeutics, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 28.5% below estimates on average.

Wall Street analysts project Carisma Therapeutics, Inc. revenue of about $9.1M for fiscal 2026, with EPS near $-0.52.

The most recent 10 insider filings for Carisma Therapeutics, Inc. break down as 5 sales and 5 purchases. On net that is roughly 257K shares acquired (about $324K) — insiders putting money in tends to read as conviction.

CARM Financials

CARM Latest News

CARM Analyst Consensus

CARM MoonshotScore

What Investors Ask About Carisma Therapeutics, Inc. (CARM) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources